Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of DirectorsGlobeNewsWire • 07/08/20
Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-CongressGlobeNewsWire • 06/29/20
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic FibrosisGlobeNewsWire • 06/22/20
Is the Options Market Predicting a Spike in Corbus Pharmaceuticals (CRBP) Stock?Zacks Investment Research • 06/18/20
Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic FibrosisGlobeNewsWire • 06/01/20
Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic SclerosisGlobeNewsWire • 05/27/20
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-CongressGlobeNewsWire • 05/22/20
Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/11/20
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/11/20
Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate UpdatesGlobeNewsWire • 05/11/20
Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & RheumatologyGlobeNewsWire • 04/29/20
3 Reasons Medical Marijuana Is a Better Long-Term Investment Than Recreational PotThe Motley Fool • 04/19/20
Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/12/20
Corbus Pharmaceuticals (CRBP) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/12/20
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial ResultsGlobeNewsWire • 03/12/20
Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent DirectorGlobeNewsWire • 03/10/20
Earnings Preview: Corbus Pharmaceuticals (CRBP) Q4 Earnings Expected to DeclineZacks Investment Research • 03/03/20
Corbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 02/11/20